Production Of GlaxoSmithKline Plc's Ziagen HIV Oral Liquid Medicine

Mots-clés

A GlaxoSmithKline Canada Inc. employee labels and packages bottles of... Photo d'actualitéAffaires,Bouteille,Canada,Conditionnement,Continent américain,Culture d'entreprise,Finance,Horizontal,Mississauga,Médicament,Métier,Ontario - Canada,SIDA,Santé et médecine,Siège social,Toronto,Travailler,Utiliser la bouche,Virus HIV,État liquide,États-Unis,ÉtiquettePhotographer Collection: Bloomberg 2010 BloombergA GlaxoSmithKline Canada Inc. employee labels and packages bottles of Ziagen, an HIV oral liquid medication, on the packaging line at the company's Canadian headquarters in Mississauga, Ontario, Canada, on Monday, Dec. 13, 2010. Global sales of existing HIV medicines will peak at $12 billion in 2012, then halve by 2019 as patent expiries increase competition from generic drugs, according to a report by Datamonitor Group earlier this year. Photographer: Norm Betts/Bloomberg via Getty Images